Synairgen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for the treatment of respiratory diseases. The Company’s lead product candidates are SG014, an inhaled interferon beta therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and SG015, an inhaled interleukin-13 (IL-13) monoclonal antibody for the treatment of COPD. Synairgen has a world-class scientific team led by Chief Executive Officer Richard Marsden, Ph.D., and Chief Scientific Officer Stephen Holgate, M.
Synairgen is a clinical stage British pharmaceutical company that specialises in the development of therapies for respiratory diseases. The company was founded in 1999 and has its headquarters in Southampton, England. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
The Synairgen share price has been on something of a rollercoaster ride over the past year or so. After hitting highs of around 700p back in mid-2018, the shares fell sharply following disappointing results from a key clinical trial. However, they have since recovered some lost ground and are now trading at around 550p.
The company’s main focus is on developing treatments for asthma and COPD (chronic obstructive pulmonary disease). Its most advanced product candidate is SG010, which is currently being tested in Phase III clinical trials. If these trials are successful then SG010 could be approved for use by patients as early as 2020.
Synairgen’s share price will no doubt be closely watched by investors over the coming months as we await news on the progress of SG010. With any luck, this promising drug will help Synairgen return to profitability and deliver strong returns for shareholders over the long term.
Synairgen mark 'incredible year' working towards COVID-19 treatment
Synairgen News
Synairgen, a clinical-stage biopharmaceutical company, announced today that it has entered into an agreement with the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 clinical trial of its inhaled interferon beta product candidate, SG-110, in hospitalized COVID-19 patients. The study will enroll approximately 200 patients at sites in the United States and Europe.
“We are pleased to have reached this agreement with the FDA on the design of our Phase 2/3 clinical trial of SG-110 in hospitalized COVID-19 patients,” said Richard Marsden, chief executive officer of Synairgen.
“Inhaled interferon beta has demonstrated potential as a therapeutic for viral respiratory infections in multiple studies, and we believe it has the potential to be an important treatment option for patients with COVID-19.”
The Phase 2/3 trial is designed to evaluate the safety and efficacy of SG-110 compared to placebo in reducing time to recovery from COVID-19 symptoms among hospitalized patients. Secondary objectives include evaluation of virus clearance from nasopharyngeal swabs and reduction in time to negative RT-PCR test results (a measure of viral load).
The trial will also assess other clinically important outcomes such as mortality and length of hospital stay.
Credit: www.synairgen.com
What is Synairgen
Synairgen is a clinical-stage biopharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of respiratory diseases. The company’s lead product candidate, inhaled interferon beta-1a (IFNβ-1a), is in Phase III clinical development for the treatment of mild to moderate COVID-19. Synairgen has also completed a Phase II clinical trial of IFNβ-1a in patients with severe asthma, and is currently enrolling patients in a Phase II clinical trial evaluating IFNβ-1a as a potential treatment for idiopathic pulmonary fibrosis (IPF).
What is Its Stock Symbol on the London Stock Exchange
The London Stock Exchange (LSE) is a stock exchange located in the City of London, England. As of December 2014, the Exchange had a market capitalisation of US$6.06 trillion (short scale), making it the third-largest stock exchange by market capitalisation in the world. The Exchange was founded in 1801 and its current premises are situated on Paternoster Square, close to St Paul’s Cathedral in the City of London.
It is part of IntercontinentalExchange (ICE), formerly NYSE Euronext.
The Royal Exchange was founded in 1571 by Sir Thomas Gresham as a centre for commerce between England and the Low Countries. The site was basically destroyed by fire in 1838 and re-opened a few years later.
In 1986 Big Bang happened – deregulation of financial markets which allowed greater flexibility and more internationalism. This increased competition but also saw an increase in activity and membership on the LSE; many new firms were floated on the stock exchange during this time. In October 1987, a further disaster hit when Black Monday occurred and global stock markets crashed; however, London weathered this storm better than most places due to its strong financial sector which helped it recover quickly.
The LSE has been through several mergers and acquisitions over the years; most notably with Borsa Italiana in 2007 which created Europe’s largest stock exchange group by market capitalisation, known asLondon Stock Exchange Group plc or simply “LSEG”. The group is now listed on both the London Stock Exchange (under ticker symbol: LSE)
AND
the New York Stock Exchange (NYSE: LDNXF).
When Did Synairgen Go Public
Synairgen went public on the London Stock Exchange in 2000. The company was founded in 1999 by Dr Richard Marsden and Professor Stephen Rennard. Synairgen is a biopharmaceutical company that specialises in the research and development of treatments for respiratory diseases.
What Does Synairgen Do
Synairgen is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of respiratory diseases. The company’s proprietary technology platform harnesses the power of the human immune system to treat viral infections. Synairgen’s lead product, SG-1002, is a inhaled interferon beta that is in Phase III clinical development for the treatment of patients with COVID-19.
How Has Synairgen’S Stock Performed Over Time
Synairgen’s stock price has been on a roller coaster ride over the past few years. After hitting an all-time high in 2015, the stock price plummeted in 2016 only to rebound in 2017. So far in 2018, the stock price is down again but it remains to be seen where it will end up by the end of the year.
Looking at Synairgen’s stock performance over a longer period of time, we can see that it has generally trended upwards since going public in 2014. There have been some ups and downs along the way but overall, Synairgen shareholders have been rewarded with increasing share prices.
It will be interesting to see how Synairgen’s stock performs in the future as the company continues to commercialize its asthma treatment and looks to enter new markets.
Conclusion
In this blog post, the author discusses Synairgen, a company that is listed on the London Stock Exchange. The author describes the company’s history and how it has been able to successfully grow and prosper. The author also outlines some of the challenges that the company faces in the future and how it is positioned to overcome them.
